310 related articles for article (PubMed ID: 23382571)
41. Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation.
Marcus JL; Hurley LB; Hare CB; Nguyen DP; Phengrasamy T; Silverberg MJ; Stoltey JE; Volk JE
J Acquir Immune Defic Syndr; 2016 Dec; 73(5):540-546. PubMed ID: 27851714
[TBL] [Abstract][Full Text] [Related]
42. Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study.
Ryom L; Dilling Lundgren J; Reiss P; Kirk O; Law M; Ross M; Morlat P; Andreas Fux C; Fontas E; De Wit S; D'Arminio Monforte A; El-Sadr W; Phillips A; Ingrid Hatleberg C; Sabin C; Mocroft A;
J Infect Dis; 2019 Oct; 220(10):1629-1634. PubMed ID: 31504669
[TBL] [Abstract][Full Text] [Related]
43. Assessment of renal function in routine care of people living with HIV on ART in a resource-limited setting in urban Zambia.
Deckert A; Neuhann F; Klose C; Bruckner T; Beiersmann C; Haloka J; Nsofwa M; Banda G; Brune M; Reutter H; Rothenbacher D; Zeier M
PLoS One; 2017; 12(9):e0184766. PubMed ID: 28931037
[TBL] [Abstract][Full Text] [Related]
44. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
[TBL] [Abstract][Full Text] [Related]
45. Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy.
Lê MP; Landman R; Koulla-Shiro S; Charpentier C; Sow PS; Diallo MB; Ngom Gueye NF; Ngolle M; Le Moing V; Eymard-Duvernay S; Benalycherif A; Delaporte E; Girard PM; Peytavin G;
J Antimicrob Chemother; 2015 May; 70(5):1517-21. PubMed ID: 25583749
[TBL] [Abstract][Full Text] [Related]
46. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy.
Rossi C; Raboud J; Walmsley S; Cooper C; Antoniou T; Burchell AN; Hull M; Chia J; Hogg RS; Moodie EE; Klein MB;
BMC Infect Dis; 2017 Apr; 17(1):246. PubMed ID: 28376824
[TBL] [Abstract][Full Text] [Related]
47. Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
Guillemi SA; Ling SH; Dahlby JS; Yip B; Zhang W; Hull MW; Lima VD; Hogg RS; Werb R; Montaner JS; Harris M
J Int AIDS Soc; 2016; 19(1):20995. PubMed ID: 27624144
[TBL] [Abstract][Full Text] [Related]
48. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
[TBL] [Abstract][Full Text] [Related]
49. Antiretroviral therapies in women after single-dose nevirapine exposure.
Lockman S; Hughes MD; McIntyre J; Zheng Y; Chipato T; Conradie F; Sawe F; Asmelash A; Hosseinipour MC; Mohapi L; Stringer E; Mngqibisa R; Siika A; Atwine D; Hakim J; Shaffer D; Kanyama C; Wools-Kaloustian K; Salata RA; Hogg E; Alston-Smith B; Walawander A; Purcelle-Smith E; Eshleman S; Rooney J; Rahim S; Mellors JW; Schooley RT; Currier JS;
N Engl J Med; 2010 Oct; 363(16):1499-509. PubMed ID: 20942666
[TBL] [Abstract][Full Text] [Related]
50. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).
De Beaudrap P; Diallo MB; Landman R; Guèye NF; Ndiaye I; Diouf A; Kane CT; Etard JF; Girard PM; Sow PS; Delaporte E;
AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1221-7. PubMed ID: 20854202
[TBL] [Abstract][Full Text] [Related]
51. Discontinuation of tenofovir due to nephrotoxicity: insight into 12 years of clinical practice.
Matłosz B; Kowalska JD; Bąkowska E; Firląg-Burkacka E; Vassilenko A; Horban A
Przegl Epidemiol; 2019; 73(2):249-255. PubMed ID: 31385682
[TBL] [Abstract][Full Text] [Related]
52. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients.
Peters L; Grint D; Lundgren JD; Rockstroh JK; Soriano V; Reiss P; Grzeszczuk A; Sambatakou H; Mocroft A; Kirk O;
AIDS; 2012 Sep; 26(15):1917-26. PubMed ID: 22781222
[TBL] [Abstract][Full Text] [Related]
53. Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy.
Lin KY; Liao SH; Liu WC; Cheng A; Lin SW; Chang SY; Tsai MS; Kuo CH; Wu MR; Wang HP; Hung CC; Chang SC
PLoS One; 2015; 10(9):e0137660. PubMed ID: 26360703
[TBL] [Abstract][Full Text] [Related]
54. Renal function and associated mortality risk in adults commencing HIV antiretroviral therapy in Zimbabwe.
Drak D; Shamu T; Heron JE; Chimbetete C; Dahwa R; Gracey DM
AIDS; 2022 Apr; 36(5):631-636. PubMed ID: 34923518
[TBL] [Abstract][Full Text] [Related]
55. Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study.
Boyd MA; Mocroft A; Ryom L; Monforte AD; Sabin C; El-Sadr WM; Hatleberg CI; De Wit S; Weber R; Fontas E; Phillips A; Bonnet F; Reiss P; Lundgren J; Law M
PLoS Med; 2017 Nov; 14(11):e1002424. PubMed ID: 29112958
[TBL] [Abstract][Full Text] [Related]
56. Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study.
Domingo P; Suarez-Lozano I; Gutierrez F; Estrada V; Knobel H; Palacios R; Antela A; Blanco JR; Fulladosa X;
Nefrologia (Engl Ed); 2019; 39(5):497-505. PubMed ID: 31027896
[TBL] [Abstract][Full Text] [Related]
57. Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy.
Calza L; Sachs M; Colangeli V; Borderi M; Granozzi B; Malosso P; Comai G; Corradetti V; La Manna G; Viale P
Clin Exp Nephrol; 2019 Nov; 23(11):1272-1279. PubMed ID: 31327092
[TBL] [Abstract][Full Text] [Related]
58. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study.
Kamara DA; Ryom L; Ross M; Kirk O; Reiss P; Morlat P; Moranne O; Fux CA; Mocroft A; Sabin C; Lundgren JD; Smith CJ;
BMC Nephrol; 2014 Mar; 15():51. PubMed ID: 24666792
[TBL] [Abstract][Full Text] [Related]
59. Serious clinical events in HIV-positive persons with chronic kidney disease.
Ryom L; Lundgren JD; Law M; Kirk O; El-Sadr W; Bonnet F; Weber R; Fontas E; Monforte AD; Phillips A; Reiss P; de Wit S; Hatleberg CI; Sabin C; Mocroft A;
AIDS; 2019 Nov; 33(14):2173-2188. PubMed ID: 31385862
[TBL] [Abstract][Full Text] [Related]
60. Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight.
Chaisiri K; Bowonwatanuwong C; Kasettratat N; Kiertiburanakul S
Curr HIV Res; 2010 Oct; 8(7):504-9. PubMed ID: 21073439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
